ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Defective efferocytosis in diabetes: molecular mechanisms and emerging therapeutic strategies.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDiabetes is associated with oxidative stress, systemic immune dysregulation and chronic low-grade inflammation, which contributes to a wide spectrum of microvascular and macrovascular complications. Efferocytosis, the phagocytic clearance of apoptotic cells by macrophages and dendritic cells, is essential for inflammation resolution and tissue repair. Defective efferocytosis has been increasingly implicated in the progression of diabetes and several of its major complications, including atherosclerosis, nephropathy, retinopathy, impaired wound healing, and osteoporosis.
objectivesThis narrative review is prepared through a focused literature search of studies investigating efferocytosis in diabetes, elucidates how its disruption contributes to the progression of diabetic complications, and further highlight emerging therapeutic strategies aimed at regulating efferocytosis. This paper is expected to provide direction and outlook for the research on efferocytosis and diabetes.
resultsEfferocytosis regulation involves a coordinated cascade of find-me signals, engulfment receptors, intracellular cytoskeletal remodeling, and metabolic reprogramming. This review summarizes the key molecular changes of defective efferocytosis and pathological changes in diabetic complications. Importantly, emerging preclinical studies have demonstrated that restoring efferocytosis ameliorate inflammation, promote tissue regeneration, and interrupt the progression of diabetic complications.
conclusionsEfferocytosis not only illuminates fundamental aspects of immune regulation but also opens up new therapeutic possibilities. As the field continues to evolve, integrating efferocytosis-based interventions into the broader therapeutic landscape of diabetes may represent a paradigm shift in the management of its chronic complications.
Indexed as
Identifiers
42329402What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.